



ProtNeteomix proposes cost-efficient microarray-based solutions for Drug Discovery & Development

One of the main challenges facing the pharmaceutical industry is the extremely high overall cost and time-consuming nature of Drug Discovery & Development (DDD). ProtNeteomix can provide faster and cheaper solutions based on innovative miniaturized and highly sensitive proprietary tools for obtaining valuable information about target proteins, and generating effective drugs to combat human diseases.

We have developed a range of diverse microarrays of small molecules, antibodies and proteins/peptides, and have successfully demonstrated their usefulness in various biomedical applications. Our high-throughput and multiplexed microarrays could form part of the early and late steps of DDD programs, including screening compound libraries, lead optimization, target validation, selecting the most appropriate candidates for pre-clinical trials. They could also be used to evaluate the safety and efficacy of drug-like leads in clinical trials.

This new approach to DDD should make it possible to speed up drug design, replace expensive *in vivo* tests by *in vitro* assays, and cut the huge expenditure wasted on evaluating compounds that subsequently prove to be “useless” because of their side effects, as well as to demonstrate the strengths of the best drug candidates.



We can assist in designing microarrays (proteins/peptides, antibodies, and small molecules) and also provide a top-class service tailored to the needs of specific DDD projects.

ProtNeteomix



ProtNeteomix SAS

2, rue de la Houssinière
44322 Nantes Cedex 3 France
Tel/Fax 33(0)2 51 12 56 26
contact@protneteomix.com